Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir for severe fever with thrombocytopenia syndrome (SFTS)
ChiCTR2400082172Phase 4Not yet recruiting
- Sponsor
- Juxian People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in severe fever with thrombocytopenia syndrome (SFTS) comparing Molnupiravir arm with Placebo arm (2 arms). Primary endpoint: 28-day all-cause mortality. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
molnupiravir
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on ChiCTR2400082172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082172.